Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.26

+1.2%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NeuroInvestment who wrote (20666)	7/28/2006 6:24:45 PM
From: Miljenko Zuanic	Read Replies (1) of 52153

Harry, NXY-059 MAY be a first-generation version of that? Anti-oxidative neuro-protection? The dose that AZN is using in SAINT is too high to indicate true protective mechanism (anti-oxidative???) that may lead to post-stroke recovery and benefit. I didn’t found any reliable data to show what percentage of the circulating drug does reach brain area (it is di-sodium salt), ncbi.nlm.nih.gov so, are there possibilities for other mechanisms or de-sulfonyation to PBN is one option …? Yes, first PIII data indicate marginal benefit, but how will FDA react if there is no benefit in NIHSS analysis is main issue here, regardless of the AZN approach to problem? I didn’t follow field for years, so would like opinion from someone more familiar with current medicine. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next